HSK46575

HSK46575 is a small molecule inhibitor of the enzyme cytochrome P450 11A1 (CYP11A1), developed by Tibet Haisco Pharmaceutical and currently in early clinical development for metastatic castration-resistant prostate cancer (mCRPC). CYP11A1 catalyzes the first step in steroid hormone biosynthesis, converting cholesterol to pregnenolone, which ultimately leads to androgen production. By inhibiting CYP11A1, HSK46575 aims to suppress androgen synthesis at an earlier point than current therapies like abiraterone or enzalutamide, potentially overcoming resistance mechanisms. Preclinical studies demonstrated that HSK46575 reduced tumor size and prostate-specific antigen (PSA) levels in models of castration-resistant prostate cancer. The drug is administered orally once daily and has shown favorable pharmacokinetics and tolerability profiles compared to other agents such as ODM-208[1][4][5].